CHRS
Coherus Oncology, Inc. NASDAQ Listed Nov 6, 2014$1.75
After hrs
$1.77
+1.14%
Mkt Cap $205.6M
52w Low $0.71
54.8% of range
52w High $2.62
50d MA $1.74
200d MA $1.53
P/E (TTM)
-1.2x
EV/EBITDA
-0.7x
P/B
3.5x
Debt/Equity
0.7x
ROE
275.4%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$1.74
200d MA
$1.53
Avg Volume
1.5M
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
333 Twin Dolphin Drive · Redwood City, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.36 | -0.34 | +4.3% | 1.93 | -3.6% | +1.0% | -7.8% | -12.4% | -15.5% | -14.0% | — |
| Nov 6, 2025 | AMC | -0.32 | -0.33 | -3.1% | 1.49 | -9.4% | -10.1% | -15.4% | -9.4% | -8.7% | -15.4% | — |
| Aug 7, 2025 | AMC | -0.31 | -0.34 | -9.7% | 0.88 | -1.1% | -7.1% | -0.4% | +3.6% | +13.0% | +15.4% | — |
| May 12, 2025 | AMC | -0.31 | -0.35 | -12.9% | 1.02 | -14.0% | -19.1% | -22.5% | -24.7% | -25.4% | -21.6% | — |
| Mar 10, 2025 | AMC | -0.10 | -0.28 | -180.0% | 1.04 | +0.0% | +1.0% | -5.8% | -14.4% | -11.5% | -12.0% | — |
| Nov 6, 2024 | AMC | -0.10 | -0.01 | +90.0% | 0.72 | +10.0% | +13.3% | +12.6% | +7.6% | +13.8% | +7.6% | — |
| Aug 8, 2024 | AMC | -0.21 | -0.14 | +33.3% | 1.29 | +12.4% | +10.9% | +13.2% | +11.6% | +6.2% | +20.2% | — |
| May 9, 2024 | AMC | -0.05 | -0.32 | -540.0% | 2.12 | +2.4% | -10.4% | -1.4% | -1.9% | +2.8% | +2.4% | — |
| Mar 13, 2024 | AMC | -0.21 | -0.62 | -195.2% | 2.30 | -8.7% | -5.7% | -3.5% | -3.5% | +6.5% | +7.8% | — |
| Nov 6, 2023 | AMC | -0.21 | -0.27 | -28.6% | 3.54 | -22.6% | -30.2% | -42.7% | -54.8% | -55.1% | -51.4% | — |
| Aug 2, 2023 | AMC | -0.52 | -0.38 | +26.9% | 4.34 | +9.4% | +17.7% | +16.8% | +15.7% | +10.4% | +5.8% | — |
| May 8, 2023 | AMC | -0.61 | -0.75 | -23.0% | 8.14 | -20.6% | -27.4% | -27.4% | -36.2% | -39.8% | -39.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4 | Maxim Group | Upgrade | Hold → Buy | — | $1.26 | $1.31 | +4.0% | +4.0% | +2.4% | +8.7% | +7.1% | +4.0% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.00 | -2.9% | -3.0% | +0.0% | +1.9% | +6.8% | -1.0% |
| Apr 24 | UBS | Maintains | Neutral → Neutral | — | $1.11 | $1.09 | -1.8% | -9.0% | -7.2% | -7.2% | -9.9% | -7.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.04 | +0.0% | +1.0% | -5.8% | -14.4% | -11.5% | -12.0% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | -2.3% | -5.3% | -11.5% | -15.3% | -6.9% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.35 | +2.3% | -0.8% | -3.0% | -6.1% | -12.1% | -15.9% |
| Dec 5 | Baird | Maintains | Outperform → Outperform | — | $1.71 | $1.80 | +5.3% | -11.7% | -0.6% | -0.6% | -5.8% | -3.5% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.82 | +6.4% | +0.0% | -11.7% | -0.6% | -0.6% | -5.8% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $0.82 | $0.83 | +1.2% | -0.6% | -5.0% | +0.4% | -5.0% | -5.8% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.72 | $0.80 | +10.0% | +13.3% | +12.6% | +7.6% | +13.8% | +7.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.32 | +1.5% | -19.2% | -20.0% | -19.2% | -13.1% | -21.5% |
| Aug 16 | UBS | Downgrade | Buy → Neutral | — | $1.55 | $1.46 | -5.8% | -18.7% | -18.7% | -19.4% | -13.5% | -14.8% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.25 | -7.4% | -2.2% | -1.5% | -8.1% | -4.4% | +5.9% |
| Jul 1 | Baird | Maintains | Outperform → Outperform | — | $1.73 | $1.73 | +0.0% | -6.9% | -19.7% | -19.7% | -23.1% | -26.6% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $2.03 | +1.0% | -5.0% | -6.5% | -8.5% | -6.5% | -9.5% |
| May 13 | Truist | Maintains | Buy → Buy | — | $1.90 | $1.92 | +1.1% | +10.0% | +9.5% | +14.7% | +14.2% | +11.6% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.12 | $2.17 | +2.4% | -10.4% | -1.4% | -1.9% | +2.8% | +2.4% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.45 | $2.40 | -2.0% | +1.2% | +2.4% | -4.9% | -6.9% | -6.1% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.10 | -8.7% | -5.7% | -3.5% | -3.5% | +6.5% | +7.8% |
| Jan 23 | Baird | Maintains | Outperform → Outperform | — | $2.58 | $2.60 | +0.8% | -7.0% | -10.9% | -8.1% | -9.3% | -10.9% |
| Jan 23 | Truist | Maintains | Buy → Buy | — | $2.58 | $2.60 | +0.8% | -7.0% | -10.9% | -8.1% | -9.3% | -10.9% |
| Dec 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $3.00 | +37.6% | +23.4% | +48.6% | +52.8% | +44.0% | +38.5% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.30 | +0.4% | +0.4% | -3.1% | -7.9% | -8.7% | +3.5% |
| Nov 28 | Truist | Maintains | Buy → Buy | — | $1.94 | $1.91 | -1.5% | +8.8% | +12.4% | +9.8% | +18.6% | +18.6% |
| Nov 8 | Maxim Group | Downgrade | Buy → Hold | — | $2.47 | $2.48 | +0.4% | -17.8% | -35.2% | -35.6% | -30.4% | -26.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $2.74 | -22.6% | -30.2% | -42.7% | -54.8% | -55.1% | -51.4% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $3.54 | $3.48 | -1.7% | -10.0% | -7.6% | -17.9% | -22.6% | -25.4% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.05 | $4.00 | -1.2% | -1.7% | -2.0% | -4.4% | -7.7% | -11.1% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $4.05 | $4.00 | -1.2% | -1.7% | -2.0% | -4.4% | -7.7% | -11.1% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.34 | $4.75 | +9.4% | +17.7% | +16.8% | +15.7% | +10.4% | +5.8% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $4.27 | $4.33 | +1.4% | -4.9% | +2.3% | +2.8% | +2.6% | -2.3% |
| Jun 28 | Truist | Maintains | Buy → Buy | — | $3.84 | $3.84 | +0.0% | +5.5% | +9.1% | +11.2% | +15.1% | +19.0% |
| Jun 20 | Truist | Maintains | Buy → Buy | — | $4.13 | $4.17 | +1.0% | -7.0% | -6.3% | -8.2% | -3.4% | -7.7% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.13 | $4.17 | +1.0% | -7.0% | -6.3% | -8.2% | -3.4% | -7.7% |
| Jun 15 | Truist | Maintains | Buy → Buy | — | $5.36 | $5.36 | +0.0% | +0.6% | -22.9% | -28.4% | -27.8% | -29.3% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $5.00 | +0.4% | +5.8% | +8.0% | +8.2% | +8.8% | +8.0% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.09 | $4.17 | +2.0% | -1.0% | +8.8% | +21.8% | +28.9% | +31.5% |
| May 23 | Barclays | Maintains | Overweight → Overweight | — | $4.46 | $4.46 | +0.0% | +2.2% | -2.7% | -3.8% | -2.5% | -7.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.14 | $6.46 | -20.6% | -27.4% | -27.4% | -36.2% | -39.8% | -39.9% |
| May 1 | Truist | Maintains | Buy → Buy | — | $7.23 | $7.49 | +3.6% | +6.1% | -0.8% | +1.0% | +1.2% | +2.1% |
| Mar 28 | UBS | Upgrade | Neutral → Buy | — | $6.00 | $6.34 | +5.7% | +7.0% | +8.0% | +7.2% | +14.0% | +24.7% |
| Mar 8 | Barclays | Maintains | Overweight → Overweight | — | $7.30 | $7.25 | -0.7% | -5.5% | -14.5% | -16.8% | -12.7% | -13.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $6.53 | -3.5% | +7.8% | +1.9% | -7.8% | -10.3% | -5.9% |
| Nov 16 | Mizuho | Maintains | Buy → Buy | — | $7.96 | $7.88 | -1.0% | -7.7% | -15.7% | -15.3% | -17.1% | -17.7% |
| Nov 14 | JP Morgan | Maintains | Neutral → Neutral | — | $7.79 | $7.72 | -0.9% | +1.9% | +2.2% | -5.6% | -13.9% | -13.5% |
| Aug 16 | Mizuho | Maintains | Buy → Buy | — | $13.87 | $14.03 | +1.2% | -3.5% | -5.7% | -6.3% | -8.8% | -11.2% |
| Jun 14 | UBS | Maintains | Neutral → Neutral | — | $6.19 | $6.28 | +1.5% | -3.1% | -3.2% | -5.3% | +1.8% | +7.3% |
| May 20 | Mizuho | Maintains | Buy → Buy | — | $7.91 | $7.97 | +0.8% | +5.1% | +1.0% | -3.0% | -6.3% | -3.2% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $8.43 | $8.10 | -3.9% | -4.7% | +1.1% | -8.1% | -10.0% | -5.7% |
| Mar 7 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.85 | $11.49 | -3.0% | -2.0% | -3.5% | +2.7% | +4.9% | +4.1% |
No insider trades available.
8-K
Coherus Oncology, Inc. -- 8-K Filing
Coherus Oncology doubled 2025 revenue to $40.8 million while slashing debt by 90% to $38.8 million, strengthening its balance sheet with $172.1 million in cash, indicating improved financial stability for investors.
Mar 9
8-K · 8.01
!! High
Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Coherus Oncology agreed to issue 28.6 million common shares to underwriters in a public offering, with underwriters granted a 30-day option to purchase additional shares.
Feb 17
8-K · 8.01
!! High
Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Coherus disclosed a material event that likely impacts near-term stock momentum; investors should monitor the announcement details for potential effects on clinical programs, partnerships, or financial guidance that could influence valuation.
Feb 4
Data updated apr 25, 2026 1:17am
· Source: massive.com